IMAGING AGENT APPROVALS SHOULD BE BASED ON STRENGTH OF DATA PROVIDED TO PRACTITIONER, CORAR TELLS FDA CMTE.; WORKABLE POINTS DUE BY MID-JANUARY
This article was originally published in The Gray Sheet
FDA should "recognize that the preapproval, development and review process" of medical imaging agents "should not be based on clinical utility or specific diseases, but on the performance of the procedure in providing information to the practitioner," according to a Council on Radionuclides and Radiopharmaceuticals statement prepared for an Oct. 26 meeting of the agency's Medical Imaging Drugs Advisory Committee in Silver Spring, Maryland.
You may also be interested in...
AMAG outlines plans for retrospective real-world evidence studies, and possibly a new placebo-controlled trial with a primary endpoint of preterm birth <32 weeks, in a filing opposing the Center for Drug Evaluation and Research’s proposal to withdraw the drug.
The leading Korean pharma firm’s oral, third-generation EGFR-TKI is approved in the country, providing a new option for patients with advanced NSCLC and increasing hopes for global approvals given an ongoing global Phase III combination trial led by partner J&J.
DePuy Synthes expects its Velys robotic-assisted system to be cost-effective, easy-to-use and to be well-suited for use in ambulatory surgery centers.